Dr. Sivagini Ganesh

Intensive Care Medicine
Keck Hospital Of USC
1500 San Pablo St, 
Los Angeles, CA 
Accepting New Patients
Referral may be required
Before you request
Keck Hospital Of USC
1500 San Pablo St, 
Los Angeles, CA 

Overview

Sivagini Ganesh is an Intensive Care Medicine provider practicing medicine in Los Angeles, California.

Her clinical expertise encompasses Pulmonary Fibrosis, Systemic Sclerosis (SSc), Secondary Immunodeficiency (SID), Gastrostomy, and Septoplasty.

She is actively involved in clinical research, co-authoring 15 peer reviewed articles and participating in 8 clinical trials. Dr. Ganesh is currently accepting new patients.

Specialties

Intensive Care Medicine

Licenses

Internal Medicine in CA

Hospital Affiliations

Keck Hospital Of USC

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Keck Hospital of USC
1500 San Pablo St, Los Angeles, CA 90033

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

RELIEVE-PAH TRIAL: REducing Right ventricuLar faIlure With thE V-waVe Shunt in Pulmonary Arterial Hypertension
RELIEVE-PAH TRIAL: REducing Right ventricuLar faIlure With thE V-waVe Shunt in Pulmonary Arterial Hypertension
Enrollment Status: Active_not_recruiting
Publish Date: June 22, 2026
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: June 16, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
Enrollment Status: Completed
Publish Date: November 01, 2024
Intervention Type: Drug
Study Drug: Treprostinil Inhalation Powder
Study Phase: Phase 1
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

15 Total Publications

Association of Foregut Testing and Intervention on Lung Transplant Outcomes.
Association of Foregut Testing and Intervention on Lung Transplant Outcomes.
Journal: Journal of clinical gastroenterology
Published: October 06, 2025
Similar Doctors
Expertise in
3
conditions
Dr. Igor Z. Barjaktarevic
Intensive Care Medicine
Expertise in
3
conditions
Dr. Igor Z. Barjaktarevic
Intensive Care Medicine
Referral may be required
Before you request

Office

200 UCLA Medical Plz Ste 365B1, 
Los Angeles, CA 
 (13.9 miles away)
310-825-8061
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Igor Barjaktarevic is an Intensive Care Medicine provider practicing medicine in Los Angeles, California. Dr. Barjaktarevic is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Emphysema, Liver Failure, Lung Nodules, Thrombectomy, and Endoscopy. Dr. Barjaktarevic is currently accepting new patients.

Expertise in
1
conditions
Dr. Zea Borok
Intensive Care Medicine
Expertise in
1
conditions
Dr. Zea Borok
Intensive Care Medicine
Referral may be required
Before you request

USC University Hospital

1520 San Pablo St Ste 1000, 
Los Angeles, CA 
 (1.0 miles away)
323-342-5100
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Zea Borok is an Intensive Care Medicine provider practicing medicine in Los Angeles, California. Dr. Borok is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Pulmonary Fibrosis. Dr. Borok is currently accepting new patients.

Expertise in
6
conditions
Dr. Kazuhide Matsushima
Intensive Care Medicine
Expertise in
6
conditions
Dr. Kazuhide Matsushima
Intensive Care Medicine
Referral may be required
Before you request

Keck Hospital Of USC

1500 San Pablo St, 
Los Angeles, CA 
 (0.1 miles away)
323-442-6254
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kazuhide Matsushima is an Intensive Care Medicine provider practicing medicine in Los Angeles, California. Dr. Matsushima is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Gallbladder Disease, Traumatic Brain Injury, Venous Thromboembolism (VTE), Gallbladder Removal, and Splenectomy. Dr. Matsushima is currently accepting new patients.

Frequently Asked Questions about Dr. Sivagini Ganesh

How do I make an appointment with Dr. Sivagini Ganesh?

You can book an appointment with Dr. Sivagini Ganesh by calling their office at 323-442-8500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sivagini Ganesh a top-rated expert for Pulmonary Fibrosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sivagini Ganesh is classified as an Experienced expert for Pulmonary Fibrosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sivagini Ganesh specialize in?

While Dr. Sivagini Ganesh is a Intensive Care Medicine, they have specific expertise in Pulmonary Fibrosis, Systemic Sclerosis (SSc), and Gastrostomy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Intensive Care Medicine.

Does Dr. Sivagini Ganesh participate in research or clinical trials?

Yes. Dr. Sivagini Ganesh has published 15 articles and abstracts on conditions like Pulmonary Fibrosis. You can view a list of Dr. Sivagini Ganesh's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sivagini Ganesh accept my insurance?

Dr. Sivagini Ganesh accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 323-442-8500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ganesh's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile